Signals, Powered By EquityPandit
Aurobindo Pharma has received the US health regulator’s approval for making and marketing its anti-infective Linezolid injection in the American market.
Aurobindo Pharma has said in a BSE filing that “The company has received final approval from the United States Food & Drug Administration (USFDA) to manufacture and market Linezolid injection, 600 mg/300 mL (2 mg/mL).”
The product launch has been expected in the second quarter of the 2016-17 fiscal.
